구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-CD19 T cell |
Overview Company | Kang YU |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B Cell Lymphoma; B Cell Leukemia |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.. Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance CAR-T function-such as cytokine co-expression-often lead to severe adverse effect… |
Toxicology CRS | Reported |
Clinical Safety signal | Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.. Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance CAR-T function-such as cytokine co-expression-often lead to severe adverse effect… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03704298 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CAR-CD19 T cell |
Overview Company | Kang YU |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | B Cell Lymphoma; B Cell Leukemia |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.. Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance CAR-T function-such as cytokine co-expression-often lead to severe adverse effect… |
Toxicology CRS | Reported |
Clinical Safety signal | Fucoidan potentiates anti-tumor efficacy of CAR-T cells against non-Hodgkin lymphoma by activation of STAT3 pathway.. Despite advances in chimeric antigen receptor T-cell (CAR-T) therapy, significant challenges remain, including progressive T-cell exhaustion and poor in vivo persistence. Current strategies to enhance CAR-T function-such as cytokine co-expression-often lead to severe adverse effect… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT03704298 |
추천 비교
추천 비교